CN109652463A - A method of using Perakine reductase synthesis of chiral alcohol - Google Patents
A method of using Perakine reductase synthesis of chiral alcohol Download PDFInfo
- Publication number
- CN109652463A CN109652463A CN201811521466.0A CN201811521466A CN109652463A CN 109652463 A CN109652463 A CN 109652463A CN 201811521466 A CN201811521466 A CN 201811521466A CN 109652463 A CN109652463 A CN 109652463A
- Authority
- CN
- China
- Prior art keywords
- perakine
- reductase
- chiral alcohol
- synthesis
- butene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a kind of methods using Perakine reductase synthesis of chiral alcohol, and using different prochiral ketones as substrate, through Perakine reductase catalyst system reduction synthesis chiral alcohol, the catalyst system is made of Perakine reductase and regenerating coenzyme system.It is heretofore described not only to have many advantages, such as that reaction step is simple, reaction condition is mild, environmental-friendly, high catalytic efficiency, enzyme purification is simple, stability is good, stereoselectivity is strong as the method for catalyst synthesis of chiral alcohol using Perakine reductase, and the substrate of Perakine reductase is extremely wide, its substrate includes acetophenones, ketene, cyclic ketone and chain ketone etc., has good industrial application development prospect in the commercial synthesis field of chiral alcohol and relevant chiral drug.
Description
Technical field
The invention belongs to technical field of biochemical industry, specifically, being not right for catalyst using Perakine reductase
The method for claiming reduction prochiral ketone to obtain the chiral alcohol of optics alcohol.
Background technique
Chiral alcohol is the intermediate of a kind of particularly important fine chemistry industry and chiral drug synthesis, is synthesized all the time standby
By the concern of researcher.Main applied chemistry and biocatalyst are at present with the symmetrical transfer reaction of not hydrogen (ATH) and asymmetric hydrogen
The mode for changing (AH) is catalyzed prochiral ketones and obtains chiral alcohol.Compared to chemical catalysis, the characteristics of biocatalysis possesses high-efficiency environment friendly,
More meet the development trend of " Green Chemistry " advocated at present.Biocatalysis mode mainly includes that whole-cell catalytic, crude enzyme liquid are urged
Change and pure enzymatic, wherein the advantage that post-processing is simple, side reaction is few is all had using pure enzyme as biocatalyst, and compared with by blueness
It looks at.The enzyme that can be applied to asymmetric reduction ketone at present mainly has short-chain dehydrogenase and ketoreductase, but due to by stability, bottom
The limitation of many factors such as object spectrum, catalytic efficiency and production of enzyme, and cannot be widely applied to the synthesis of chiral alcohol, therefore researcher
Still constantly looking for the new ketoreductase that can be used for chiral alcohol synthesis.
Perakine reductase (Perakine Reductase) derives from Apocynaceae Rauwolfia medicinal plant serpentaria
Wooden (Rauvolfia serpentina Benth.ex Kurz), it is super for aldehyde ketone reductase (Aldo-KetoReductase, AKR)
The member of family, enzymatic aldehyde ketone reduction reaction (Sun L, Ruppert M, the Sheludko Y, Warzecha supplemented by NADPH
H,Zhao Y, J.Purification,cloning,functional expression and
characterization of perakine reductase:the first example from the AKR enzyme
family,extending the alkaloidal network of the plant Rauvolfia.Plant Mol
Biol.2008,67(5):455-67.)。
Summary of the invention
It is an object of that present invention to provide a kind of methods using Perakine reductase synthesis of chiral alcohol.This method has vertical
The features such as body is selectively good, high conversion efficiency, reaction step are simple, and transformable prochiral ketone type is various.
A kind of method using Perakine reductase synthesis of chiral alcohol provided by the invention, using prochiral ketone as substrate,
Corresponding chiral alcohol is obtained through the catalysis of enzymatic system, the enzymatic system is by Perakine reductase and regenerating coenzyme system
Composition.
Specific steps are as follows: using prochiral ketone as raw material, using NADPH as coenzyme, urged in the asymmetry of Perakine reductase
Under change, reduction generates corresponding chiral alcohol, and reaction equation is as follows:
NADPH is oxidized to NADP during the reaction+, but NADPH is expensive, it is therefore desirable to which regenerating coenzyme system is by NADP+It is regenerated as NADPH.
Specifically, Perakine reductase derives from plant snakewood (Rauvolfia serpentina Benth.ex
Kurz), amino acid sequence such as PR-AA (SEQ.No.2) in sequence table is shown.
Amino acid is by lacking, being inserted into or replace one or several amino acid in amino acid sequence shown in any couple of PR-AA
And with Perakine reductase activity, still fall within protection scope of the present invention.
Specifically, the nucleotide sequence such as PR-DNA (SEQ.No.1) institute in sequence table of coding Perakine reductase gene
Show；
As it is known by the man skilled in the art, the nucleotide sequence of Perakine reductase gene of the invention is also possible to compile
Other any nucleotide sequences of the protein of amino acid sequence composition shown in PR-AA in code sequence table.
Nucleotide sequence shown in any couple of PR-AA carries out the substitution of one or more nucleotide, certain or insertion process obtains
The nucleotide sequence obtained all belongs to the scope of protection of the present invention as long as it has 90% or more homology with nucleotide.
In the present invention, the regenerating coenzyme system are as follows: using glucose dehydrogenase be coenzyme regeneration enzyme, using glucose as coenzyme
It regenerates substrate, include NADPH and NADP+Glucose dehydrogenase regenerating coenzyme system.
Enzymatic system of the present invention includes Perakine reductase, glucose dehydrogenase, glucose and micro NADP+.Prochiral ketone is added to the enzyme reaction system, under conditions of controlling pH and temperature, which can be by latent chirality
Ketone is converted into corresponding chiral alcohol.Reaction principle is as shown in Fig. 1.Perakine reductase and coenzyme in the enzymatic system
Regeneration enzyme is after purification the pure enzyme that dissociates.
Preferably, the glucose dehydrogenase derives from bacillus megaterium.
Specifically, the glucose dehydrogenase derives from bacillus megaterium (Bacillus megaterium) IAM1030
Glucose dehydrogenase.
Preferably, in catalyst system, the additive amount of the Perakine reductase and glucose dehydrogenase is 0.1~
3mg/ml。
In catalyst system, the additive amount of substrate prochiral ketone is 0.1~20mM；The additive amount of regenerating coenzyme substrate is 0.15
~30mM.
Preferably, in enzymatic system, reaction temperature is 20~55 DEG C, the reaction time is 0.5~for 24 hours；It is further preferred that warm
Degree is 30~40 DEG C, and the time is 2~10h.
Preferably, the pH value of control reaction is 6~9, the decline of pH is controlled using sodium hydroxide, is controlled using formic acid
The rising of pH processed.
The prochiral ketone substrate of the Perakine reductase and the structure of chiral alcohol product are respectively provided with following general formula (I)
(II), R1And R2For different groups.
Further, the prochiral ketone substrate of the Perakine reductase includes and is not limited in following compound: benzene
Ethyl ketone (1), 4 '-nitro-acetophenones (2), 4 '-chloro-acetophenones (3), 4 '-bromoacetophenones (4), 4 '-methoxyacetophenones (5), 2 '-
Bromoacetophenone (6), 3 '-bromoacetophenones (7), 3 '-aminoacetophenones (8), 2- chloro-acetophenone (9), 2,2 ', 4 '-trichloroacetophenones
(10), (E)-4- phenyl-3- butene-2 -one (11), (E)-4- (4- nitro-phenyl)-3- butene-2 -one (12), (E)-4- (4-
Methoxyl group-phenyl)-3- butene-2 -one (13), (E)-4- (2,4- Dichloro-phenyl)-3- butene-2 -one (14), (E)-4- (3-
Bromophenyl)-3- butene-2 -one (15), (E)-4- (3- oxo but-1-ene-1- base) benzonitrile (16), (E)-4- (2- furyl)-
3- butene-2 -one (17), (E)-4- (benzo [d] [1,3] dioxole-5- base)-3- butene-2 -one (18), 4- phenyl-
2- butanone (19), (E) -4- (4- hydroxy phenyl) -2- butanone (20), 1- phenyl -2,3- diketone (21), ethyl pyruvate (22),
2 pentanone (23), 4-methyl-2 pentanone (24), 3- methyl cyclohexanone (25), structural formula is as follows:
The beneficial effects are mainly reflected as follows: it provides one kind and is led to using Perakine reductase as biocatalyst
The method that asymmetric reduction prochiral ketone synthesizes high optical homochiral alcohol is crossed, is had not been reported yet；It is urged with other ketoreductases
Change system ratio, heretofore described Perakine reductase catalyst system have following distinguishing feature, substrate adaptability is extremely strong,
High catalytic efficiency, stereoselectivity are high, stability is good, easily prepared, while it is mild, environmental-friendly etc. raw also to have reaction condition
The advantage of object catalysis, great industrial applications development prospect.
Detailed description of the invention
Fig. 1 is that Perakine used by the method for the present invention is restored in enzyme system with glucose dehydrogenase regeneration coenzyme synthesis
The reaction equation of chiral alcohol.
Fig. 2 is the figure of Perakine reductase SDS-PAGE after purification.
Fig. 3 is the figure of glucose dehydrogenase SDS-PAGE after purification.
Fig. 4 is the blank control of 4- nitro-acetophenone and reaction solution is high after Perakine reductase catalyst system reacts 10h
Effect liquid phase chromatogram figure.
Fig. 5 is Perakine reductase catalyst system reaction product p-nitrophenyl ethyl alcohol chiral resolution chromatogram.
Specific embodiment
Below in conjunction with specific embodiment, the present invention will be further described.It should be understood that following embodiment is merely to illustrate this
The range of invention and is not intended to limit the present invention.
Experimental method in the present invention is conventional method unless otherwise instructed.
Plasmid extraction kit is purchased from the Hangzhou Axygen Co., Ltd in the present invention；E.coli M15, plasmid pQE-2 are purchased from
Qiagen company；E.coli DH5 α, E.coli BL (DE3) are purchased from Novagen company；Pre-dyed albumen Maker is purchased from
Fermantas company.
Prochiral ketone substrate, NADPH, NADP used in the present invention+It is purchased from Sigma-Aldrich company；Other
Common agents are purchased from Sinopharm Chemical Reagent Co., Ltd..
Catalysis reaction of the invention is monitored by high performance liquid chromatography (HPLC), and to each reaction substrate and product into
Row analysis.HPLC analysis method are as follows: chromatograph Agilent high performance liquid chromatography 1100；Chromatographic column250-
4RP-select-B(250x 4mm,5μm)；25 DEG C of column temperature；Flow velocity 1ml/min；Detection wavelength 254nm；Mobile phase: water 50%~
70%, acetonitrile 50%~30%.
Chiral alcohol product involved in the present invention is split by efficient liquid phase chiral column.Chromatograph Shimadzu LC-2010AHT/
2010CHT；Chiral chromatographic column (Chiral HPLC Columns) is respectivelyAD-H (I.D:4.6mm,
Length:250mm, 5 μm；AD-H) withOD-H (I.D:4.6mm, Length:150mm, 5 μm；OD-H)；Stream
Fast 0.5mL/min；Detection wavelength 254nm；Mobile phase: isopropanol 3%~10%, n-hexane 97%~90%.
The expression of embodiment 1Perakine reductase
By Perakine reductase expression vector, in early-stage study building complete (Sun L, Ruppert M,
Sheludko Y,Warzecha H,Zhao Y, J.Purification,cloning,functional
expression and characterization of perakine reductase:the first example from
the AKR enzyme family,extending the alkaloidal network of the plant
Rauvolfia.Plant Mol Biol.2008,67 (5): 455-67.), thermal shock is transformed into E.coli M15 competent cell,
It obtains Perakine and restores expression of enzymes engineering bacteria.Perakine reduction expression of enzymes engineering bacteria is seeded to containing 50 μ g/ml ammonia benzyls
37 DEG C of shaken cultivation 12h in the LB culture medium of XiLin and 25 μ g/ml kanamycins.It is forwarded to 1L and contains same concentrations ampicillin
In the LB culture medium of kanamycins, as the optical density OD of culture solution600When reaching 0.6, the isopropyl of final concentration of 0.3mM is added
After 25 DEG C of induction 30h of base-β-D- Thiogalactopyranoside (IPTG), culture solution 8000rpm is centrifuged 10min, is obtained
Perakine restores expression of enzymes engineering bacteria, and -20 DEG C save for use.
The expression of 2 glucose dehydrogenase of embodiment
Encode the glucose dehydrogenase gene of bacillus megaterium (Bacillus megaterium) IAM1030
(GenBank:D10626.1), such as sequence table GDH-DNA, amino acid sequence such as sequence table GDH-AA.Glucose dehydrogenase gene
By Sangon Biotech (Shanghai) Co., Ltd. it is fully synthetic after be connected into pET-28a (+) carrier, after sequence verification sequence, thermal shock turns
Change to E.coli BL21 (DE3) competent cell, obtains glucose dehydrogenase and express engineering bacteria.Glucose dehydrogenase is expressed
Engineering bacteria is seeded to 37 DEG C of shaken cultivation 12h in the LB culture medium containing 50 μ g/ml kanamycins.Be forwarded to 1L contain it is identical dense
It spends in the LB culture medium of kanamycins, as the optical density OD of culture solution600When reaching 0.6, the IPTG of final concentration of 0.1mM is added
After 20 DEG C of induction 16h, by culture solution 8000rpm be centrifuged 10min, Perakine restore expression of enzymes engineering bacteria, -20 DEG C save to
With.
The purifying of embodiment 3Perakine reductase and glucose dehydrogenase
Perakine reduction expression of enzymes engineering bacteria or glucose dehydrogenase expression engineering bacteria somatic cells are resuspended in 20ml and split
Solve liquid (10mM imidazoles, 50mM NaH2PO4, 300mM NaCl, pH 8.0) in, the bacteriolyze of 1-2mg/ml is added in oscillation after shaking up
Enzyme after ice bath 40min, sets ultrasonic disruption 3 times, and 3min/ times, every minor tick 15min.Broken 22000 × g of liquid is centrifuged 50min,
Gained supernatant is crude enzyme liquid.Using Ni-NTA as purified material, packed column volume 3ml, 15ml lysate balances Ni-NTA column,
With the rate loading crude enzyme liquid of 1ml/min, with washing buffer (20mM imidazoles, 50mM NaH2PO4, 300mM NaCl, pH
8.0) elution removes unadsorbed albumen, finally uses elution buffer (250mM imidazoles, 50mM NaH2PO4, 300mM NaCl, pH
8.0) target protein is collected in elution, with 5L Kpi buffer (50mM KH2PO4, 50mM K2HPO4, 10mM EDTA, pH 7.0)
Dialysis target protein, removes desalination and imidazoles, and 4 DEG C of the pure enzyme solution of gained saves backup, and SDS-PAGE is analyzed the results show that Perakine
The purity of reductase (attached drawing 2) and glucose dehydrogenase (attached drawing 3) is 95% or more.
Embodiment 4Perakine reductase reduction system prochiral ketone synthesis of chiral alcohol (by taking 4 '-nitro-acetophenones as an example)
In the present invention enantiomeric excess value (e.e.) of chiral alcohol product by calculation formula e.e.=([S]-[R])/
([R]+[S]) * 100% is calculated, and [S] and [R] is respectively chromatographic peak area value.
By in embodiment 3 gained Perakine reductase and the pure enzyme of glucose dehydrogenase according to concentration 1mg/ml additive amount
It is added in reaction system, using 50mM pH 7.0Kpi as buffer, then is separately added into the 4 '-nitrobenzenes of final concentration of 0.8mM
Ethyl ketone, 1.2mM glucose, 0.02mM NADP+10h is reacted in 30 DEG C of constant temperature oscillations (175rpm).Reaction solution is through isometric second
Acetoacetic ester extraction is control, chiral efficient liquid with p-nitrophenyl ethyl alcohol racemic modification and (S) -4- Nitrophenethyl alcohol standard items
GC headspace analysis measures e.e. value > 99.9% of -4 '-Nitrophenethyl alcohol of chiral alcohol product (S), yield 99%, accordingly
Reaction high-efficient liquid phase chromatogram is shown in that attached drawing 4, product alcohol hand split chromatogram and see attached drawing 5.
Embodiment 5Perakine reductase catalyst system converts prochiral ketone compound (1) according to condition described in embodiment 3
The yield and e.e. Value Data of~(25) are as shown in table 1 below.
Table 1
Sequence table
<110>Zhejiang University
<120>a kind of method using Perakine reductase synthesis of chiral alcohol
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1014
<212> DNA
<213>artificial sequence (Unknown)
<400> 1
atgccaagag ttaagctggg aacccaaggg ctcgaggttt caaaattagg atttggctgt 60
atggggcttt ccggagacta caatgatgct cttcctgagg agcaaggaat tgcagttatc 120
aaggaggcct tcaattgtgg aataacattc tttgatacat cagatattta tggcgagaac 180
ggttctaatg aagaattgct cgggaaggca ctgaaacaat tgcctcgaga aaagatccag 240
gtgggaacga agtttggtat acatgagatt ggtttttctg gggtcaaagc taaaggtact 300
ccagactatg tccgctcctg ctgtgaggct agcctgaagc gccttgatgt ggactatatc 360
gatctcttct acatacatcg catagataca acagtgccta ttgagataac tatgggtgaa 420
cttaagaagt tagttgaaga aggaaaaata aagtacgttg ggctatctga agctagtccg 480
gacacaataa ggagggcaca tgccgttcat cctgtaactg ctttacaaat tgagtattct 540
ctgtggacac gggacattga agacgagata gtgcctctgt gcagacaact cggaattggc 600
atagttccat acagccctat tggccggggt ctttttgccg ggaaggccat taaggaaagc 660
cttccagaaa acagtgtctt gacatcacat cccagatttg ttggggagaa ccttgaaaag 720
aacaagcaaa tatattatcg tatagaagca ttgtcacaaa agcatggatg tactcctgtt 780
caacttgctc ttgcttgggt tcttcatcag ggcgaagatg ttgtacctat tcctggtacc 840
acaaagataa aaaatcttca caataatgtt ggtgctctga aagtaaagct cacgaaagaa 900
gatttgaaag agatttctga tgcagttcct cttgatgagg tggccgggga gagcatccat 960
gaagttattg ctgtgaccaa ctggaagttt gccaatacac caccattgaa gtaa 1014
<210> 2
<211> 337
<212> PRT
<213>artificial sequence (Unknown)
<400> 2
Met Pro Arg Val Lys Leu Gly Thr Gln Gly Leu Glu Val Ser Lys Leu
1 5 10 15
Gly Phe Gly Cys Met Gly Leu Ser Gly Asp Tyr Asn Asp Ala Leu Pro
20 25 30
Glu Glu Gln Gly Ile Ala Val Ile Lys Glu Ala Phe Asn Cys Gly Ile
35 40 45
Thr Phe Phe Asp Thr Ser Asp Ile Tyr Gly Glu Asn Gly Ser Asn Glu
50 55 60
Glu Leu Leu Gly Lys Ala Leu Lys Gln Leu Pro Arg Glu Lys Ile Gln
65 70 75 80
Val Gly Thr Lys Phe Gly Ile His Glu Ile Gly Phe Ser Gly Val Lys
85 90 95
Ala Lys Gly Thr Pro Asp Tyr Val Arg Ser Cys Cys Glu Ala Ser Leu
100 105 110
Lys Arg Leu Asp Val Asp Tyr Ile Asp Leu Phe Tyr Ile His Arg Ile
115 120 125
Asp Thr Thr Val Pro Ile Glu Ile Thr Met Gly Glu Leu Lys Lys Leu
130 135 140
Val Glu Glu Gly Lys Ile Lys Tyr Val Gly Leu Ser Glu Ala Ser Pro
145 150 155 160
Asp Thr Ile Arg Arg Ala His Ala Val His Pro Val Thr Ala Leu Gln
165 170 175
Ile Glu Tyr Ser Leu Trp Thr Arg Asp Ile Glu Asp Glu Ile Val Pro
180 185 190
Leu Cys Arg Gln Leu Gly Ile Gly Ile Val Pro Tyr Ser Pro Ile Gly
195 200 205
Arg Gly Leu Phe Ala Gly Lys Ala Ile Lys Glu Ser Leu Pro Glu Asn
210 215 220
Ser Val Leu Thr Ser His Pro Arg Phe Val Gly Glu Asn Leu Glu Lys
225 230 235 240
Asn Lys Gln Ile Tyr Tyr Arg Ile Glu Ala Leu Ser Gln Lys His Gly
245 250 255
Cys Thr Pro Val Gln Leu Ala Leu Ala Trp Val Leu His Gln Gly Glu
260 265 270
Asp Val Val Pro Ile Pro Gly Thr Thr Lys Ile Lys Asn Leu His Asn
275 280 285
Asn Val Gly Ala Leu Lys Val Lys Leu Thr Lys Glu Asp Leu Lys Glu
290 295 300
Ile Ser Asp Ala Val Pro Leu Asp Glu Val Ala Gly Glu Ser Ile His
305 310 315 320
Glu Val Ile Ala Val Thr Asn Trp Lys Phe Ala Asn Thr Pro Pro Leu
325 330 335
Lys
<210> 3
<211> 786
<212> DNA
<213>artificial sequence (Unknown)
<400> 3
atgtatacag atttaaaaga taaagtagtt gtaattacag gtggatcaac aggtttagga 60
cgtgcaatgg ctgttcgttt cggtcaagaa gaagcaaaag ttgttattaa ctattacaac 120
aatgaagaag aagctttaga tgcgaaaaaa gaagtagaag aagcaggcgg acaagcaatc 180
atcgttcaag gcgacgtaac aaaagaagaa gacgttgtaa accttgttca aacagctatt 240
aaagaattcg gaacattaga cgttatgatt aataacgctg gtgttgaaaa cccagttcct 300
tctcatgagc tatctttaga caactggaac aaagttattg atacaaactt aacaggtgca 360
ttcttaggaa gccgtgaagc aattaaatat ttcgttgaaa atgacattaa aggaaacgtt 420
attaacatgt ccagcgttca cgaaatgatt ccttggccat tatttgttca ctacgcagca 480
agtaaaggcg gtatgaaact aatgacggaa acattggctc ttgaatatgc gccaaaaggt 540
atccgagtaa ataacattgg accaggtgcg atgaacacac caattaacgc tgaaaaattc 600
gctgatcctg tacaacgtgc agacgtagaa agcatgattc caatgggtta catcggtaag 660
ccagaagaag tagcagcagt tgcagcattc ttagcatcat cacaagcaag ctatgtaaca 720
ggtattacat tatttgctga tggtggtatg acgaaatacc cttctttcca agcaggaaga 780
ggctaa 786
<210> 4
<211> 261
<212> PRT
<213>artificial sequence (Unknown)
<400> 4
Met Tyr Thr Asp Leu Lys Asp Lys Val Val Val Ile Thr Gly Gly Ser
1 5 10 15
Thr Gly Leu Gly Arg Ala Met Ala Val Arg Phe Gly Gln Glu Glu Ala
20 25 30
Lys Val Val Ile Asn Tyr Tyr Asn Asn Glu Glu Glu Ala Leu Asp Ala
35 40 45
Lys Lys Glu Val Glu Glu Ala Gly Gly Gln Ala Ile Ile Val Gln Gly
50 55 60
Asp Val Thr Lys Glu Glu Asp Val Val Asn Leu Val Gln Thr Ala Ile
65 70 75 80
Lys Glu Phe Gly Thr Leu Asp Val Met Ile Asn Asn Ala Gly Val Glu
85 90 95
Asn Pro Val Pro Ser His Glu Leu Ser Leu Asp Asn Trp Asn Lys Val
100 105 110
Ile Asp Thr Asn Leu Thr Gly Ala Phe Leu Gly Ser Arg Glu Ala Ile
115 120 125
Lys Tyr Phe Val Glu Asn Asp Ile Lys Gly Asn Val Ile Asn Met Ser
130 135 140
Ser Val His Glu Met Ile Pro Trp Pro Leu Phe Val His Tyr Ala Ala
145 150 155 160
Ser Lys Gly Gly Met Lys Leu Met Thr Glu Thr Leu Ala Leu Glu Tyr
165 170 175
Ala Pro Lys Gly Ile Arg Val Asn Asn Ile Gly Pro Gly Ala Met Asn
180 185 190
Thr Pro Ile Asn Ala Glu Lys Phe Ala Asp Pro Val Gln Arg Ala Asp
195 200 205
Val Glu Ser Met Ile Pro Met Gly Tyr Ile Gly Lys Pro Glu Glu Val
210 215 220
Ala Ala Val Ala Ala Phe Leu Ala Ser Ser Gln Ala Ser Tyr Val Thr
225 230 235 240
Gly Ile Thr Leu Phe Ala Asp Gly Gly Met Thr Lys Tyr Pro Ser Phe
245 250 255
Gln Ala Gly Arg Gly
260
Claims (10)
1. a kind of method using Perakine reductase synthesis of chiral alcohol, which is characterized in that using prochiral ketone as substrate, through enzyme
Catalyst system catalysis obtains corresponding chiral alcohol, and the enzymatic system is by Perakine reductase and regenerating coenzyme system group
At.
2. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1, which is characterized in that logical
Cross following steps realization: using prochiral ketone as raw material, using NADPH as coenzyme, the Perakine reductase in enzymatic system
Under asymmetry catalysis, reduction generates corresponding chiral alcohol, reaction equation:
NADPH is oxidized to NADP during the reaction+, by regenerating coenzyme system by NADP+It is regenerated as NADPH.
3. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In Perakine reductase derives from plant snakewood (Rauvolfia serpentina Benth.ex Kurz), amino
Acid sequence encodes the nucleotide sequence of Perakine reductase gene as shown in SEQ.No.1 as shown in SEQ.No.2.
4. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In the regenerating coenzyme system are as follows: using glucose dehydrogenase as coenzyme regeneration enzyme, using glucose as regenerating coenzyme substrate, include
NADPH and NADP+Glucose dehydrogenase regenerating coenzyme system.
5. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In the enzymatic system includes Perakine reductase, glucose dehydrogenase, glucose and micro NADP+, the enzymatic
Perakine reductase and regenerating coenzyme enzyme are after purification the pure enzyme that dissociates in system.
6. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 5, which is characterized in that institute
State the glucose dehydrogenase that glucose dehydrogenase derives from bacillus megaterium (Bacillus megaterium) IAM1030.
7. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In in enzymatic system, the additive amount of the Perakine reductase and glucose dehydrogenase is 0.1~3mg/ml.
8. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In in enzymatic system, the additive amount of substrate prochiral ketone is 0.1~20mM；The additive amount of regenerating coenzyme substrate be 0.15~
30mM, reaction temperature be 20~55 DEG C, the reaction time be 0.5~for 24 hours.
9. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In the pH value for controlling reaction is 6~9.
10. a kind of method using Perakine reductase synthesis of chiral alcohol according to claim 1 or 2, feature exist
In prochiral ketone is selected from following compound: acetophenone, 4 '-nitro-acetophenones, 4 '-chloro-acetophenones, 4 '-bromoacetophenones, 4 '-first
Oxygroup acetophenone, 2 '-bromoacetophenones, 3 '-bromoacetophenones, 3 '-aminoacetophenones, 2- chloro-acetophenone, 2,2 ', 4 '-trichloro-benzenes second
Ketone, (E)-4- phenyl-3- butene-2 -one, (E)-4- (4- nitro-phenyl)-3- butene-2 -one, (E)-4- (4- methoxyl group-benzene
Base)-3- butene-2 -one, (E)-4- (2,4- Dichloro-phenyl)-3- butene-2 -one, (E)-4- (3- bromophenyl)-3- butene-2-
Ketone, (E)-4- (3- oxo but-1-ene-1- base) benzonitrile, (E)-4- (2- furyl)-3- butene-2 -one, (E)-4- (benzo [d]
[1,3] dioxole-5- base)-3- butene-2 -one, 4- Phenyl 2 butanone, (E)-4- (4- hydroxy phenyl)-2- butanone,
1- phenyl -2,3- diketone, ethyl pyruvate, 2 pentanone, 4-methyl-2 pentanone, 3- methyl cyclohexanone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811521466.0A CN109652463B (en) | 2018-12-12 | 2018-12-12 | Method for synthesizing chiral alcohol by using Perakine reductase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811521466.0A CN109652463B (en) | 2018-12-12 | 2018-12-12 | Method for synthesizing chiral alcohol by using Perakine reductase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109652463A true CN109652463A (en) | 2019-04-19 |
| CN109652463B CN109652463B (en) | 2020-05-08 |
Family
ID=66113341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811521466.0A Active CN109652463B (en) | 2018-12-12 | 2018-12-12 | Method for synthesizing chiral alcohol by using Perakine reductase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109652463B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110373420A (en) * | 2019-06-19 | 2019-10-25 | 南京趣酶生物科技有限公司 | A kind of preparation method and application of new enzyme bacterial strain and enzyme catalyst |
| CN110408638A (en) * | 2019-06-19 | 2019-11-05 | 南京趣酶生物科技有限公司 | The preparation method of lipoic acid chirality alcohol intermediate and its preparation method of new enzyme catalyst |
| CN112538468A (en) * | 2020-12-09 | 2021-03-23 | 浙江大学 | Perakine reductase mutant and application thereof |
| CN112899321A (en) * | 2019-11-19 | 2021-06-04 | 上海天慈国际药业有限公司 | Preparation method of Laratinib key intermediate |
| CN114540321A (en) * | 2022-01-27 | 2022-05-27 | 沈阳药科大学 | Preparation method of R-2-sulfonyl-1-phenylethanol derivative |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103122355A (en) * | 2012-12-12 | 2013-05-29 | 杭州师范大学 | Recombinant heat resisting aldehyde ketoreductase gene, coding enzyme, vector, engineering bacteria and application |
-
2018
- 2018-12-12 CN CN201811521466.0A patent/CN109652463B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103122355A (en) * | 2012-12-12 | 2013-05-29 | 杭州师范大学 | Recombinant heat resisting aldehyde ketoreductase gene, coding enzyme, vector, engineering bacteria and application |
Non-Patent Citations (4)
| Title |
|---|
| CINDY ROSENTHAL，等: "Expression, purification, crystallization and preliminary X-ray analysis of perakine reductase,a new member of the aldo-keto reductase enzyme superfamily from higher plants", 《ACTA CRYSTALLOGR SECT F STRUCT BIOL CRYST COMMUN》 * |
| LIANLI SUN，等: "Crystal Structure of Perakine Reductase, Founding Member of a Novel Aldo-Keto Reductase (AKR) Subfamily That Undergoes Unique Conformational Changes during NADPH Binding", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
| LIANLI SUN，等: "Purification, cloning, functional expression and characterization of perakine reductase: the first example from the AKR enzyme family, extending the alkaloidal network of the plant Rauvolfia", 《PLANT MOLECULAR BIOLOGY VOLUME》 * |
| MENGYAN HE，等: "Efficient Preparation of (S)-N-Boc-3-Hydroxylpiperidine Through Bioreduction by a Thermostable Aldo-Keto Reductase", 《APPL BIOCHEM BIOTECHNOL》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110373420A (en) * | 2019-06-19 | 2019-10-25 | 南京趣酶生物科技有限公司 | A kind of preparation method and application of new enzyme bacterial strain and enzyme catalyst |
| CN110408638A (en) * | 2019-06-19 | 2019-11-05 | 南京趣酶生物科技有限公司 | The preparation method of lipoic acid chirality alcohol intermediate and its preparation method of new enzyme catalyst |
| CN112899321A (en) * | 2019-11-19 | 2021-06-04 | 上海天慈国际药业有限公司 | Preparation method of Laratinib key intermediate |
| CN112538468A (en) * | 2020-12-09 | 2021-03-23 | 浙江大学 | Perakine reductase mutant and application thereof |
| CN112538468B (en) * | 2020-12-09 | 2022-05-06 | 浙江大学 | Perakine reductase mutant and application thereof |
| CN114540321A (en) * | 2022-01-27 | 2022-05-27 | 沈阳药科大学 | Preparation method of R-2-sulfonyl-1-phenylethanol derivative |
| CN114540321B (en) * | 2022-01-27 | 2024-04-02 | 沈阳药科大学 | Preparation method of R-2-sulfonyl-1-phenylethanol derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109652463B (en) | 2020-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109652463A (en) | A method of using Perakine reductase synthesis of chiral alcohol | |
| KR101910259B1 (en) | Transaminase and use thereof | |
| CN111094557B (en) | Alcohol dehydrogenase mutant and application thereof in synthesis of diaryl chiral alcohol | |
| CN106701698B (en) | Carbonyl reductase, mutant and its preparing the application in antimycotic pharmaceutical intermediate | |
| KR20160089492A (en) | Omega-transaminase of r configuration and use thereof | |
| EP3650537A1 (en) | Use of stereoselective transaminase in asymmetric synthesis of chiral amine | |
| KR20090033864A (en) | Process for production of optically active alcohol | |
| CN102492668B (en) | Carbonyl reductase and gene thereof as well as application of carbonyl reductase in asymmetrical reductive carbonyl compound | |
| CN101952453B (en) | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | |
| TW200305645A (en) | Novel carbonyl reductase, gene encoding the same and process for producing optically active alcohols using the same | |
| JP6442399B2 (en) | Modified carbonyl reductase and its gene | |
| JP2020109102A (en) | Method of producing pitavastatin calcium | |
| CN111154735B (en) | Preparation method of ketene reductase and brivaracetam intermediate | |
| EP2562253A1 (en) | Modified carbonyl reductase, gene thereof, and method of producing optically active alcohols using these | |
| CN105018439B (en) | A kind of carbonyl reductase and its application in synthesis of chiral hydroxy compounds | |
| WO2004083163A1 (en) | 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO | |
| CN112708644B (en) | Preparation method of florfenicol intermediate | |
| CN108048423B (en) | Kidney bean epoxide hydrolase mutant with improved catalytic activity and application thereof | |
| CN105803013B (en) | A method of utilizing carbonyl reductase asymmetric syntheses duloxetine intermediate | |
| CN105950595B (en) | (-)-gamma-lactam enzyme, gene, mutant, carrier and its preparation and application | |
| CN112538468B (en) | Perakine reductase mutant and application thereof | |
| CN104846025B (en) | A kind of method for preparing (2S, 3R) -2- benzoyl aminomethyls -3-hydroxybutyrate methyl esters | |
| CN110438194B (en) | Application of lipase in preparation of D-tropine methyl ester | |
| EP2955225A1 (en) | (R)-selective hydroxynitrile lyase variants with a cupin fold having improved substrate scope and the use thereof | |
| CN110951711A (en) | Esterase with activity of degrading chiral ester and encoding gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |